Correction of excessive anticoagulation with low-dose oral vitamin K-1

被引:86
作者
Weibert, RT
Le, DT
Kayser, SR
Rapaport, SI
机构
[1] UNIV CALIF SAN FRANCISCO, SCH PHARM, SAN FRANCISCO, CA 94143 USA
[2] UNIV CALIF SAN DIEGO, SCH MED, LA JOLLA, CA 92093 USA
关键词
D O I
10.7326/0003-4819-126-12-199706150-00005
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Despite earlier acceptance of oral Vitamin K-1 (phytonadione) for the treatment of excessive anticoagulation, some recent guidelines do not recommend its use. Objective: To reevaluate the efficacy of oral vitamin K-1 in correcting excessive anticoagulation. Design: Case series. Setting: Anticoagulation clinics at two university medical centers. Patients: 81 outpatients who had an international normalized ratio (INR) greater than 5.0 but did not have significant bleeding. Interventions: Withholding 1 or 2 doses of warfarin, administering 2.5 mg of oral vitamin K-1, measuring the INR after 24 to 48 hours, and adjusting the warfarin dose. Measurements: INRs were obtained from a portable capillary fingerstick monitor or from an automated photo-optical coagulometer. Results: In 68 of 71 patients (96%), oral vitamin K-1 lowered the INR from between 5.0 and 10.0 to less than 5.0 without inducing resistance to further anticoagulation. Conclusions: Withholding 1 or 2 doses of warfarin and administering 2.5 mg of oral vitamin K-1 is a reliable, safe, and inexpensive way to rapidly correct excessive anticoagulation (INR > 5.0) in patients who do not have serious bleeding episodes and have an INR of less than 10.0.
引用
收藏
页码:959 / 962
页数:4
相关论文
共 16 条
[1]  
ANDERSEN P, 1975, ACTA MED SCAND, V198, P269
[2]   Optimal intensity of oral anticoagulant therapy after myocardial infarction [J].
Azar, AJ ;
Cannegieter, SC ;
Deckers, JW ;
Briet, E ;
vanBergen, PFMM ;
Jonker, JJC ;
Rosendaal, FR .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1996, 27 (06) :1349-1355
[3]   ANTITHROMBOTIC THERAPY - AN ABBREVIATED REFERENCE FOR CLINICIAN [J].
BECKER, RC ;
ANSELL, J .
ARCHIVES OF INTERNAL MEDICINE, 1995, 155 (02) :149-161
[4]   OPTIMAL ORAL ANTICOAGULANT-THERAPY IN PATIENTS WITH MECHANICAL HEART-VALVES [J].
CANNEGIETER, SC ;
ROSENDAAL, FR ;
WINTZEN, AR ;
VANDERMEER, FJM ;
VANDENBROUCKE, JP ;
BRIET, E .
NEW ENGLAND JOURNAL OF MEDICINE, 1995, 333 (01) :11-17
[6]   CONSERVATIVE TREATMENT OF OVERANTICOAGULATED PATIENTS [J].
GLOVER, JJ ;
MORRILL, GB .
CHEST, 1995, 108 (04) :987-990
[8]   MECHANISM OF ACTION, CLINICAL EFFECTIVENESS, AND OPTIMAL THERAPEUTIC RANGE [J].
HIRSH, J ;
DALEN, JE ;
DEYKIN, D ;
POLLER, L ;
BUSSEY, H .
CHEST, 1995, 108 (04) :S231-S246
[9]   BLEEDING COMPLICATIONS TO ORAL ANTICOAGULANT-THERAPY - MULTIVARIATE-ANALYSIS OF 1010 TREATMENT YEARS IN 551 OUTPATIENTS [J].
LAUNBJERG, J ;
EGEBLAD, H ;
HEAF, J ;
NIELSEN, NH ;
FUGLEHOLM, AM ;
LADEFOGED, K .
JOURNAL OF INTERNAL MEDICINE, 1991, 229 (04) :351-355
[10]   HEMORRHAGIC COMPLICATIONS OF ANTICOAGULANT TREATMENT [J].
LEVINE, MN ;
RASKOB, G ;
LANDEFELD, S ;
HIRSH, J .
CHEST, 1995, 108 (04) :S276-S290